« Previous
Next »
Titles
- Safeguards must be strengthened to protect Medicare hospice beneficiaries from harm1
- Safety and performance based pathway: guidance for industry and Food and Drug Administration1
- Safety stories: missing the mark1
- School discipline practices associated with adolescent school connectedness and engagement1
- Section 1115 Medicaid demonstration waivers: the current landscape of approved and pending waivers1
- Separating fact from fiction: recommendations for academic health centers on artificial and augmented intelligence1
- Severely debilitating or life-threatening hematologic disorders: nonclinical development of pharmaceuticals1
- Siponimod for the treatment of secondary progressive multiple sclerosis: effectiveness and value : final evidence report1
- Small-business owners' views on health coverage and costs1
- Smallpox (variola virus) infection: developing drugs for treatment or prevention1
- Social Security replacement rates and other benefit measures: an in-depth analysis1
- Social Security’s financial outlook: the 2019 update in perspective1
- Social care 3601
- Some Medicare Part D beneficiaries face avoidable extra steps that can delay or prevent access to prescribed drugs1
- Sources and preparation of data used in HISIM2: CBO’s health insurance simulation model1
- Spending on individuals with type 1 diabetes and the role of rapidly increasing insulin prices1
- Spinraza and Zolgensma for spinal muscular atrophy: effectiveness and value : final evidence report1
- Spotlight on national behavioral health trends: a 10-year window into key mental health and substance abuse indicators1
- Standards development and the use of standards in regulatory submissions reviewed in the Center for Biologics Evaluation and Research1
- State Children's Health Insurance Program (SCHIP)1